However, it is important to note that plasma concentrations both itaconate and GM-CSF did not significantly increase with MDR-TB treatment, suggesting alternative mechanisms are able to reverse proinflammatory metabolic signaling cascades. The gene discussed is CSF2; the disease is tuberculosis.